Hodgkin's Lymphoma after Initiation of Antiretroviral Therapy in a Patient from India

• Published in: Indian journal of public health Vol. 68; no. 3; pp. 454 - 456
• Main Authors: Konan, Vinay Kumar, Kavya, S T, Nagchand, Mohan C, Shetty, Bhushan C
• Format: Journal Article
• Language: English
• Published: India Medknow Publications & Media Pvt. Ltd 01.07.2024; Wolters Kluwer Medknow Publications
• Subjects: abvd; Adult; Anti-Retroviral Agents - adverse effects; Anti-Retroviral Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Antiretroviral agents; antiretroviral disease; Bleomycin - administration & dosage; Bleomycin - adverse effects; CD4 Lymphocyte Count; Dacarbazine - adverse effects; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; HIV; HIV Infections - drug therapy; Hodgkin Disease - drug therapy; hodgkin’s lymphoma; Human immunodeficiency virus; Humans; India; Lymphoma; Male; malignancy; Vinblastine - administration & dosage; Vinblastine - adverse effects; Vinblastine - therapeutic use; Weight loss; India
• ISSN: 0019-557X; 2229-7693
• DOI: 10.4103/ijph.ijph_1285_23

Malignancies in human immunodeficiency virus (HIV) positive individuals have a larger role in morbidity and mortality. Appropriate clinical acumen is required for a clinician to anticipate the occurrence of lymphoma after starting antiretroviral therapy, especially in patients with CD4 <100 cells/mm3. Here is a 30-year-old man with weight loss and appetite, found to be retroviral disease positive status with low CD 4 counts. He was started on antiretroviral treatment, and following that, he developed Hodgkin's lymphoma of mixed cellularity. He is planned for an ABVD regimen and received one cycle of the same without any complications. To our knowledge, we are reporting the first case of an HIV patient with a mixed cellularity form of classical Hodgkin's lymphoma from India.